Clinical trials: Carcinoma, Transitional Cell
Melanoma, Urothelial Carcinoma
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive…
- Trial name
- NCT05496192
- Testing
- Nivolumab/rHuPH20, Nivolumab
- Where
- 3 sites in Germany, Spain
- Sponsor
- Bristol-Myers Squibb
Ureteral Stricture, Hydronephrosis
Water Versus Saline as Irrigation Fluid for Ureteroscopy
The purpose of this study is to determine the rate of absorption of fluids (water or saline) during ureteroscopy and to assess the effects on electrolyte levels.
- Conditions
- Ureteral Stricture, Hydronephrosis, Urothelial Carcinoma, Urolithiasis
- Trial name
- NCT03794102
- Testing
- Water, Saline
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Urinary Bladder Neoplasms
Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure
This is a Phase I, open-label, multicenter, dose-escalation study that aims to evaluate the safety and tolerability of intravesical inactivated Instillations of UPEC-FimON (Uro-Pathogenic E.
- Trial name
- NCT07881666
- Testing
- Inactivated UPEC-FimON
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Hopec Pharma
Urothelial Carcinoma
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
- Trial name
- NCT07789119
- Testing
- biospecimen Collection
- Where
- United States
- Volunteers
- 50,000 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma, Anlotinib
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first…
- Conditions
- Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms, Cisplatin
- Trial name
- NCT05030077
- Testing
- Anlotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Muscle Invasive Bladder Cancer Urothelial Carcinoma
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study
This is a single-arm, open-label, multicenter clinical trial to investigate the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder…
- Trial name
- NCT05328336
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tianjin Medical University Second Hospital
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Urothelial Carcinoma, Breast Cancer
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
This study is a diagnostic study. Patients and healthy volunteers with clinically suspected or confirmed urothelial carcinoma, breast cancer, lung carcinoma and other malignant tumors with high expression of Nectin-4 will be…
- Conditions
- Urothelial Carcinoma, Breast Cancer, Lung Carcinoma
- Trial name
- NCT06994078
- Testing
- 68Ga-NOTA-Nectin-4 antibody fragment
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Urothelial Carcinoma
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
The purpose of this study is to see how well the study drugs called Ipilimumab plus Nivolumab (IPI-NIVO) work when added to another study drug called Sacituzumab Govitecan for people who have metastatic bladder cancer.
- Trial name
- NCT04863885
- Testing
- Ipilimumab, Nivolumab, Sacituzumab govitecan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
RATIONALE: Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01222676
- Testing
- cisplatin, gemcitabine hydrochloride, sorafenib tosylate
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urothelial Carcinoma
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
The purpose of this study is to learn if ipilimumab can be given safely at two different doses given to patients with urothelial cancer who are going to have surgery as part of their treatment.
- Trial name
- NCT00362713
- Testing
- Ipilimumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Urothelial Carcinoma, Diagnoses Disease
UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis.
Upper tract urothelial carcinoma (UTUC) diagnosis include urography using computed tomography urography (CTU) or urography using MRI (MRU). The sensitivity of CTU decreases substan¬tially with decreasing lesion size.
- Conditions
- Urothelial Carcinoma, Diagnoses Disease, Ureter Cancer, IMAGE
- Trial name
- NCT05043662
- Testing
- UroCAD assay, CTU examination and urine cytology
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Changhai Hospital
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma…
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03682289
- Testing
- Ceralasertib, Olaparib, Durvalumab
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Rahul Aggarwal
Urothelial Carcinoma
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
This is a feasibility trial of anti-PDL1/PD1 (pembrolizumab) and stereotactic body radiation therapy (SBRT) in patients with advanced, platinum-refractory urothelial carcinoma.
- Trial name
- NCT03287050
- Testing
- Pembrolizumab, SBRT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer
Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma
Purpose：To evaluate whether immediate multiparametric MRI evaluate the sensitivity of modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer（MIBC）.
- Trial name
- NCT04588168
- Testing
- Chemotherapy, Immediate Multiparametric MRI, Cystectomy and Lymphadenectomy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Urothelial Cancer
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer
- Trial name
- NCT00790426
- Testing
- TKI258
- Where
- 26 sites in United States, Austria and 6 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Urothelial Carcinoma
A Study of GEN1106 in Participants With Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts.
- Trial name
- NCT07416123
- Testing
- GEN1106
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 103 people
- Sponsor
- Genmab
Urothelial Carcinoma
Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma
The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.
- Trial name
- PREVAIL (NCT03788746)
- Where
- 58 sites in United States
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.